Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

Summary by Eastern Progress
NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024),…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Eastern ProgressEastern Progress

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024),…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Eastern Progress broke the news in on Thursday, August 14, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Nanjing icon

Nanjing

News
For You
SearchBlindspotLocal